输注不同治疗剂量血小板在56例急性淋巴细胞白血病患儿中的临床观察*

doi:10.3969/j.issn.1671-2587.2022.02.016

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (2): 218-221.DOI: 10.3969/j.issn.1671-2587.2022.02.016

输注不同治疗剂量血小板在56例急性淋巴细胞白血病患儿中的临床观察^*

刘琴, 徐春芬, 宋婕, 谢松丽, 陈涵薇, 胡红兵

430015 华中科技大学同济医学院附属武汉儿童医院（武汉市妇幼保健院）输血科（刘琴,徐春芬,胡红兵）; 江汉大学（宋婕）; 武汉血液中心（谢松丽,陈涵薇）

收稿日期:2021-11-12 发布日期:2022-04-12
通讯作者: 胡红兵,女,主任技师,硕士,主要从事临床输血研究,（E-mail）whfesx@163.com。
作者简介:刘琴（1981-）,女,副主任技师,硕士,主要从事临床输血研究,（E-mail）liuqin20051224@aliyun.com。
基金资助:
*本课题受湖北省卫生健康科研基金（No.WJ2019H339）,江汉大学大学生学术科技项目（No.2020yb260）资助

Clinical Observation of Different Therapeutic dose Platelets in 56 Pediatric Patients with Acute Lymphoblastic Leukemia

LIU Qin, XU Chun-fen, SONG Jie, et al

Department of Blood Transfusion,Wuhan Children's Hospital Affiliated to Tongji College,Huazhong University of Science and Technology 430015

Received:2021-11-12 Published:2022-04-12

摘要/Abstract

摘要： 目的评价输注不同治疗剂量血小板在急性淋巴细胞白血病患儿中的疗效及安全性。方法回顾性分析56例急性淋巴细胞白血病患儿483例次血小板输注的情况。根据单位体表面积实际血小板输注剂量,分为低剂量组：<2.2×10¹¹/m²;中剂量组：2.2~4.4×10¹¹/m²;高剂量组：>4.4×10¹¹/m²。计算24小时血小板计数增加指数（CCI）,并记录输血过程中的不良反应事件,分析比较不同输注剂量血小板之间的有效性及安全性。结果各组血小板输注的有效率和不良反应发生率差异均无统计学意义。在有效输注例次中,各组之间CCI值差异无统计学意义,但血小板增加值（PPI）存在统计学差异。结论在急性淋巴细胞白血病患儿中,血小板输注剂量不是输注有效性的主要影响因素,高剂量血小板输注并不能提高血小板CCI,0.5个治疗剂量血小板在儿科应用中具有可行性。

关键词: 血小板输注, 剂量, 急性淋巴细胞白血病, 儿科

Abstract: Objective To evaluate the efficacy and safety of different dose of platelets in pediatric patients with acute lymphoblastic leukemia. Methods It was a retrospective analysis of 483 platelet transfusions in 56 pediatric patients with acute lymphoblastic leukemia. All cases were divided into three groups according to the actual infusion dose per unit body surface area. Low dose group：<2.2×10¹¹/m²,middle dose group：2.2~4.4×10¹¹/m²,high dose group：>4.4×10¹¹/m². The 24-h platelet count increase index（CCI）was calculated and adverse reaction events were recorded during transfusion. We compared the efficacy between different transfusion doses,and analyzed the CCI values in the effective infusion cases. Results There were no significant differences for the effective rate of platelet transfusion and adverse reaction rate among the three groups. In the effective transfusion cases,there was no statistical difference in CCI values between the groups,but in PPI values,there was statistical difference. Conclusion In children with acute lymphocytic leukemia,the platelet infusion dose is not a major influencing factor of the efficacy. And the high-dose platelet infusion does not improve the platelet count increase index. The 0.5 therapeutic dose of platelets are feasible in pediatric application.

Key words: Platelet transfusion, Transfusion dose, Acute lymphoblastic leukemia, Pediatric

中图分类号:

R457

刘琴, 徐春芬, 宋婕, 谢松丽, 陈涵薇, 胡红兵. 输注不同治疗剂量血小板在56例急性淋巴细胞白血病患儿中的临床观察^*[J]. 临床输血与检验, 2022, 24(2): 218-221.

LIU Qin, XU Chun-fen, SONG Jie, et al. Clinical Observation of Different Therapeutic dose Platelets in 56 Pediatric Patients with Acute Lymphoblastic Leukemia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(2): 218-221.

参考文献

[1] NELLIS M E,GOEL R,KARAM O,et al.International study of the epidemiology of platelet transfusions in critically ill children with an underlying oncologic diagnosis[J].Pediatr Crit Care Med,2019,20(7):e342-e351.
[2] SCHIFFER C A,BOHLKE K,DELANEY M,et al.Platelet transfusion for patients with cancer:American society of clinical oncology clinical practice guideline update[J]. J Clin Oncol,2018,36(3):283-299.
[3] LEIBOWITZ M,WOLFE H,FLYNN A,et al.Standardization of prophylactic platelet transfusion dosing in a pediatric oncology population:a quality improvement project[J]. Transfusion,2018,58(12):2836-2840.
[4] LI G,ZHOU Z H,YAO L,et al.Full annotation of serum virome in Chinese blood donors with elevated alanine aminotransferase levels[J]. Transfusion,2019,59(10):3177-3185.
[5] CHEN J,OU-YANG J,XIE G,et al.Problems and challenges:development of blood transfusion services in Mainland China within the context of health-care system reform[J]. Transfus Med,2019,29(4):253-261.
[6] 周文彪. 血液资源供需失衡原因分析和对策[J].中国卫生产业,2017,14(11):195-196.
[7] HUMBRECHT C,KIENTZ D,GACHET C.Platelet transfusion:current challenges[J].Transfus Clin Biol,2018,25(3):151-164.
[8] STEVENSON P H.Height.weight.surface formula for the estimation of surface area in Chinese subjects[J]. chinese journal of physiology, 1937,12: 327-334.
[9] TRACHTENBERG F L,ASSMANN S F,TRIULZI D J,et al.Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial[J]. Vox Sang,2016,111(3):281-291.
[10] UHL L,ASSMANN S F,HAMZA T H,et al.Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial[J]. Blood,2017,130(10):1247-1258.
[11] REBULLA P.Formulae for the definition of refractoriness to platelet transfusion[J]. Transfus Med,1993,3(1):91-93.
[12] HOD E,SCHWARTZ J.Platelet transfusion refractoriness[J]. Br J Haematol,2008,142(3):348-360.
[13] COHN C S.Platelet transfusion refractoriness:how do I diagnose and manage?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532.
[14] ESTCOURT L J,STANWORTH S,DOREE C,et al. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev,2015,10(10):CD010984.
[15] KAUFMAN R M,ASSMANN S F,TRIULZI D J,et al.Transfusion-related adverse events in the Platelet Dose study[J]. Transfusion,2015,55(1):144-153.
[16] 洪缨. 浓缩血小板的制备工艺及输注安全性[J]. 中国输血杂志,2018,31(9):1086-1090.
[17] ESTCOURT L J,BIRCHALL J,ALLARD S,et al.Guidelines for the use of platelet transfusions[J]. Br J Haematol,2017,176(3):365-394.

输注不同治疗剂量血小板在56例急性淋巴细胞白血病患儿中的临床观察^*

Clinical Observation of Different Therapeutic dose Platelets in 56 Pediatric Patients with Acute Lymphoblastic Leukemia

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	王倩, 杨李辉, 丁天凌, 夏荣. 自体造血干细胞移植中不同预处理方案与血小板输注的临床分析^*[J]. 临床输血与检验, 2021, 23(6): 686-692.
[2]	敬媛媛, 王洁, 李冬妹, 王丽君, 范成艳, 贾延军. 免疫性血小板输注无效患者HLA和/或HPA抗体产生的影响因素分析[J]. 临床输血与检验, 2021, 23(6): 723-727.
[3]	唐雯, 袁君, 严京梅, 吴毅, 齐清, 栾建凤, 刘太香, 吴敏慧, 史丽莉, 冯晨晨, 薛敏. 抗体特异性预测方法克服HLA-Ⅰ类抗体所致血小板输注无效患者1例^*[J]. 临床输血与检验, 2021, 23(6): 797-799.
[4]	胡婷婷, 王诗铭, 王希文, 海艳秋, 孙婷. 肿瘤患者输注血小板发生不良反应影响因素分析[J]. 临床输血与检验, 2021, 23(4): 464-468.
[5]	张佳思, 谭方方, 袁嘉, 符刚, 阮潜瑛, 姜盛, 黎诗琦, 钱程. CAR-T治疗急性白血病患者严重并发症CRS与CRES救治的规范化护理^*[J]. 临床输血与检验, 2021, 23(3): 384-388.
[6]	王慧茹, 刘会兰. 非血缘脐血移植术后患者输血情况相关影响因素分析^*[J]. 临床输血与检验, 2021, 23(2): 162-166.
[7]	强萍, 薛磊, 汪敏, 许汉英, 刘欣, 朱薇波, 杨林, 王兴兵. 成功救治2例CAR-T细胞治疗后伴严重细胞因子风暴和相关性脑病伴文献复习[J]. 临床输血与检验, 2020, 22(4): 413-419.
[8]	王皓, 郭兴莹, 张志波, 张新萍, 冀春红, 黄象艳. HLA与HPA配型不合导致血小板输注无效1例[J]. 临床输血与检验, 2020, 22(3): 334-336.
[9]	黄雪原, 陈秉宇, 周明, 马现君, 陈静, 许红, 蔡丹, 胡俊, 谢毓滨, 桂嵘, 王勇军. 血小板抗体检测的多中心临床应用调查——基于中国10家单位的2 338例病例对照研究[J]. 临床输血与检验, 2020, 22(2): 113-117.
[10]	李冬妹, 王洁, 敬媛媛, 单小燕, 贾延军. 血小板输注无效患者体内C1q-HLA抗体的临床意义[J]. 临床输血与检验, 2020, 22(2): 126-130.
[11]	周明, 陈洋, 王敏, 潘健, 王慧茹. 机采血小板储存损伤对临床疗效的影响^*[J]. 临床输血与检验, 2019, 21(2): 129-133.
[12]	任思婳, 金晶纯, 金丽, 周文玲. 国内外血小板输注现状的分析[J]. 临床输血与检验, 2019, 21(2): 217-221.
[13]	卢信彤. 我国血小板输注阈值研究的meta分析[J]. 临床输血与检验, 2018, 20(5): 470-475.
[14]	龚道方,龙海波,刘昭国,谭云洪. 临床276例次单采血小板输注效果及相关因素分析[J]. 临床输血与检验, 2018, 20(4): 365-367.
[15]	王淑英, 周文辉, 李新颖, 张扬丽, 牛国涛, 冯艳青. 肝病患者血小板输注情况调查分析[J]. 临床输血与检验, 2017, 19(4): 328-331.